Guardant Health Inc.(GH),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

GH Guardant Health Inc.

Market Closed 01-09 16:00:00 EST

110.17

+1.43

+1.32%

盘后109.00

-1.17-1.06%

19:58 EST

High112.40	Low106.97	Vol2.41M
Open108.17	D1 Closing108.74	Amplitude4.99%
Mkt Cap14.25B	Tradable Cap13.66B	Total Shares129.37M
T/O263.68M	T/O Rate1.95%	Tradable Shares124.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"GH","market":"US","secType":"STK","nameCN":"Guardant Health Inc.","latestPrice":110.17,"timestamp":1767992400000,"preClose":108.74,"halted":0,"volume":2412034,"hourTrading":{"tag":"盘后","latestPrice":109,"preClose":110.17,"latestTime":"19:58 EST","volume":17001,"amount":1873149.4027,"timestamp":1768006712759},"delay":0,"floatShares":124000000,"shares":129374422,"eps":-3.212374,"marketStatus":"Market Closed","change":1.43,"latestTime":"01-09 16:00:00 EST","open":108.17,"high":112.4,"low":106.97,"amount":263684678.47581,"amplitude":0.049936,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.212374,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1768208400000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1538625600000,"exchange":"NASDAQ","adjPreClose":108.74,"preHourTrading":{"tag":"盘前","latestPrice":107.09,"preClose":108.74,"latestTime":"09:27 EST","volume":1113,"amount":120848.71638,"timestamp":1767968870025},"postHourTrading":{"tag":"盘后","latestPrice":109,"preClose":110.17,"latestTime":"19:58 EST","volume":17001,"amount":1873149.4027,"timestamp":1768006712759},"volumeRatio":0.9347475692251823,"impliedVol":0.6664,"impliedVolPercentile":0.6853},"requestUrl":"/m/hq/s/GH","defaultTab":"news","newsList":[{"id":"2602309071","title":"Guardant Health Chief People Officer Terilyn J. Monroe Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2602309071","media":"Reuters","labels":["insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602309071?lang=en_us&edition=fundamental","pubTime":"2026-01-10 05:10","pubTimestamp":1767993032,"startTime":"0","endTime":"0","summary":"Terilyn J. Monroe, Chief People Officer of Guardant Health Inc., reported a disposal of common shares of Guardant Health Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Guardant Health Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 09, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260109:nNDL3hzxpX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Guardant Health Chief People Officer Terilyn J. Monroe Reports Disposal of Common Shares","news_tag":"insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4551","GH","BK4588","BK4196","BK4535"],"gpt_icon":0},{"id":"2602830682","title":"Clinical Labs Hope to Head Off Looming Medicare Cuts -- Barrons.com","url":"https://stock-news.laohu8.com/highlight/detail?id=2602830682","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602830682?lang=en_us&edition=fundamental","pubTime":"2026-01-10 03:24","pubTimestamp":1767986640,"startTime":"0","endTime":"0","summary":"U.S. House representatives heard the clinical lab industry plead yesterday for a reprieve from looming cuts as large as 15% in what Medicare pays Labcorp Holdings, Quest Diagnostics and cancer-testing specialists like Guardant Health, Exact Sciences, and Natera.Starting February, a current law will require labs to tell Medicare the rates that private insurers paid for tests back in 2019. Medicare will then cut its own test payments to those levels in 2027.That will hurt the development of technologies like the genomic tests now used for diagnosing cancer patients and sick infants, said American Clinical Laboratory Association President Susan Van Meter, at a Thursday hearing on Medicare reimbursement rates.The February deadline exists because of a law passed 10 years ago that made clinical labs the only healthcare industry whose Medicare rates would match those paid by private insurers. Commercial rates were first surveyed in 2016 and Medicare cut its test payments by up to 10% in each ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LU2237438978.USD","BK4550","BK4139","LU0950375773.USD","LU1861558580.USD","GH","LH","HOPE","LU0742534661.SGD","BK4211","BK4567","LU1854103824.USD","BK4588","LU0048573561.USD","LU1854104046.USD","LU2506951875.HKD","BK4551","LU0251131958.USD","LU0823417653.USD","BK4583","LU0251142724.SGD","LU2506951958.HKD","LU1861559042.SGD","BK4535","LU1059921491.USD","BK4196","EXAS","LU0006061336.USD","LU0823417737.USD","DGX","LU2506952170.USD","BK4548","LU0266013472.USD","LU2324357040.USD","LU2506952097.USD"],"gpt_icon":0},{"id":"2601628483","title":"GH Research to Present Six-Month Safety and Efficacy Data on Inhaled GH001 in Depression at 2026 ACNP Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2601628483","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601628483?lang=en_us&edition=fundamental","pubTime":"2026-01-08 21:17","pubTimestamp":1767878278,"startTime":"0","endTime":"0","summary":"An update from GH Research ( ($GHRS) ) is now available. On January 8, 2025, GH Research PLC reported that it will present new clinical data from i...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/gh-research-to-present-six-month-safety-and-efficacy-data-on-inhaled-gh001-in-depression-at-2026-acnp-meeting?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/gh-research-to-present-six-month-safety-and-efficacy-data-on-inhaled-gh001-in-depression-at-2026-acnp-meeting?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4196","BK4535","BK4551","BK4585","BK4588","GH"],"gpt_icon":0},{"id":"2601383989","title":"GH Research Up Over 18%, On Track for Largest Percent Increase Since February 2025 -- Data Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2601383989","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601383989?lang=en_us&edition=fundamental","pubTime":"2026-01-08 02:38","pubTimestamp":1767811080,"startTime":"0","endTime":"0","summary":"GH Research Plc  is currently at $16.70, up $2.58 or 18.24%. --Would be highest close since July 21, 2025, when it closed at $19.50. --On pace for largest percent increase since Feb. 3, 2025, when it rose 69.72%. --Down 40.16% from its all-time closing high of $27.90 on Nov. 9, 2021. --Up 85.91% from 52 weeks ago , when it closed at $8.98. --Down 14.38% from its 52-week closing high of $19.50 on July 21, 2025","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4535","BK4551","BK4539","BK4196","BK4588","BK4007","GH","GHRS","BK4585"],"gpt_icon":0},{"id":"2601839996","title":"Guardant Health Cut to In-Line From Outperform by Evercore ISI Group","url":"https://stock-news.laohu8.com/highlight/detail?id=2601839996","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601839996?lang=en_us&edition=fundamental","pubTime":"2026-01-06 02:10","pubTimestamp":1767636600,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/GH/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 05, 2026 13:10 ET (18:10 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4585","BK4551","BK4535","BK4196","GH"],"gpt_icon":0},{"id":"2601835711","title":"Guardant Health Is Maintained at Buy by Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2601835711","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601835711?lang=en_us&edition=fundamental","pubTime":"2026-01-06 01:10","pubTimestamp":1767633000,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/GH/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 05, 2026 12:10 ET (17:10 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GH","BK4588","BK4535","BK4196","BK4585","BK4551"],"gpt_icon":0},{"id":"2601838540","title":"Altimmune, GH Research, Gyre Therapeutics And Other Big Stocks Moving Higher On Monday","url":"https://stock-news.laohu8.com/highlight/detail?id=2601838540","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601838540?lang=en_us&edition=fundamental","pubTime":"2026-01-05 23:09","pubTimestamp":1767625740,"startTime":"0","endTime":"0","summary":"U.S. stocks were higher, with the Dow Jones index gaining more than 500 points on Monday.Shares of Altimmune Inc  rose sharply during Monday's session after the FDA granted Breakthrough Therapy Designation for Pemvidutide in MASH.Altimmune shares jumped 23.6% to $4.34 on Monday.Here are some other big stocks recording gains in today’s session.","market":"sh","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/01/05/Section-Of-A-Financial-Newspaper-Titled-_1.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/01/05/Section-Of-A-Financial-Newspaper-Titled-_1.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/trading-ideas/movers/26/01/49694843/altimmune-gh-research-gyre-therapeutics-and-other-big-stocks-moving-higher-on-monday","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/trading-ideas/movers/26/01/49694843/altimmune-gh-research-gyre-therapeutics-and-other-big-stocks-moving-higher-on-monday","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["BK4599","GH","BK4588","GYRE","LU1878469433.USD","BK4139","BK4196","ALT","BK4585","BK4535","BK4551"],"gpt_icon":0},{"id":"2601891328","title":"GH Research Price Target Maintained With a $19.00/Share by Needham","url":"https://stock-news.laohu8.com/highlight/detail?id=2601891328","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601891328?lang=en_us&edition=fundamental","pubTime":"2026-01-05 20:49","pubTimestamp":1767617340,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/GHRS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 05, 2026 07:49 ET (12:49 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GH"],"gpt_icon":0},{"id":"2601388663","title":"GH Research Announces FDA Lifts Clinical Hold on GH001, Clearing Path for Global Phase 3 Initiation in 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2601388663","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601388663?lang=en_us&edition=fundamental","pubTime":"2026-01-05 20:00","pubTimestamp":1767614400,"startTime":"0","endTime":"0","summary":"GH001 cleared by FDA for U.S. clinical investigation, enabling U.S. subject enrollmentCompany to seek FDA alignment on global Phase 3 program replicating Phase 2b designPhase 3 initiation targeted for","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/05/3212617/0/en/GH-Research-Announces-FDA-Lifts-Clinical-Hold-on-GH001-Clearing-Path-for-Global-Phase-3-Initiation-in-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4535","BK4551","BK4585","GH","IND","BK4196"],"gpt_icon":0},{"id":"2601021650","title":"Why GH Research Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket","url":"https://stock-news.laohu8.com/highlight/detail?id=2601021650","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601021650?lang=en_us&edition=fundamental","pubTime":"2026-01-05 17:27","pubTimestamp":1767605220,"startTime":"0","endTime":"0","summary":"Shares of GH Research PLC  rose sharply in pre-market trading after the company announced it will provide an update on its FDA IND status and Phase 3 program for GH001 in treatment-resistant depression.GH Research shares jumped 18.1% to $15.64 in the pre-market trading session.Here are some other stocks moving in pre-market trading.","market":"hk","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/01/05/Section-Of-A-Financial-Newspaper-Titled-.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/01/05/Section-Of-A-Financial-Newspaper-Titled-.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/news/26/01/49684842/why-gh-research-shares-are-trading-higher-by-18-here-are-20-stocks-moving-premarket","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/26/01/49684842/why-gh-research-shares-are-trading-higher-by-18-here-are-20-stocks-moving-premarket","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["BK4535","BK4588","GHRS","BK4585","BK4196","BK4551","GH","BK4007","BK4539"],"gpt_icon":0},{"id":"2600096867","title":"Stocks to Watch: GH Research, PBF Energy, BigBear.ai","url":"https://stock-news.laohu8.com/highlight/detail?id=2600096867","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2600096867?lang=en_us&edition=fundamental","pubTime":"2026-01-03 07:17","pubTimestamp":1767395820,"startTime":"0","endTime":"0","summary":"GH Research will provide an update on its application for a therapy for treatment-resistant depression with the Food and Drug Administration as well as its Phase 3 study of the drug on Monday morning. The company said in November it was working with experts to address a remaining hold on its application for the treatment. The stock climbed 19% to $15.71 in after-hours trading.PBF Energy expects its efforts to restore a refinery damaged in a fire early last year will continue into February. The company said it expects to achieve planned operating rates at the beginning of March at its facility in Martinez, Calif. It had previously projected to restart operations at the end of last year. The stock rose 1.3%, to $28.91, after the market close.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4535","PBF","BK4588","BK4138","BK4551","GH","BK4585","BK4196"],"gpt_icon":0},{"id":"2600509870","title":"GH Research to Announce IND Status for GH001","url":"https://stock-news.laohu8.com/highlight/detail?id=2600509870","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2600509870?lang=en_us&edition=fundamental","pubTime":"2026-01-03 05:01","pubTimestamp":1767387660,"startTime":"0","endTime":"0","summary":"DUBLIN, Jan.  02, 2026   -- GH Research PLC , a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today reported that it will provide an update on the status of its Investigational New Drug Application  for GH001 with the U.S. Food and Drug Administration  and its global pivotal Phase 3 program in treatment-resistant depression  on Monday, January 5, 2026, at 7.00 a.m. EST. About GH Research PLC GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression. GH Research PLC's initial focus is on developing its novel and proprietary mebufotenin therapies for the treatment of patients with TRD. About GH001 Our lead product candidate, GH001, is formulated for mebufotenin administration via a proprietary inhalation approach. Based on the observed clinical activity in our Phase 2b GH001-TRD-","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/02/3212274/0/en/GH-Research-to-Announce-IND-Status-for-GH001.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4196","BK4551","BK4588","BK4535","IND","GH","BK4585"],"gpt_icon":0},{"id":"2595758171","title":"Guardant Health to Present at J.P. Morgan Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2595758171","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595758171?lang=en_us&edition=fundamental","pubTime":"2025-12-30 05:05","pubTimestamp":1767042328,"startTime":"0","endTime":"0","summary":"Guardant Health Inc. will participate in the 44th Annual J.P. Morgan Healthcare Conference in San Francisco. The company's management is scheduled to present and join a Q&A session on Monday, January 12, at 3:45 p.m. Pacific Time. Interested parties can access live and archived webcasts of the session on the Investors section of the Guardant Health website.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Guardant Health Inc. published the original content used to generate this news brief via Business Wire  on December 29, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251229:nNDL9PRKC7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4551","BK4535","GH","BK4585","BK4588","BK4196"],"gpt_icon":0},{"id":"2593480800","title":"Guardant Health Is Maintained at Buy by Canaccord Genuity","url":"https://stock-news.laohu8.com/highlight/detail?id=2593480800","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593480800?lang=en_us&edition=fundamental","pubTime":"2025-12-22 21:00","pubTimestamp":1766408400,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/GH/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 22, 2025 08:00 ET (13:00 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4535","BK4585","GH","BK4588","BK4551","BK4196"],"gpt_icon":0},{"id":"2593531144","title":"Is It Too Late To Consider Guardant Health After Its 215% Surge In 2025?","url":"https://stock-news.laohu8.com/highlight/detail?id=2593531144","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593531144?lang=en_us&edition=fundamental","pubTime":"2025-12-21 02:14","pubTimestamp":1766254448,"startTime":"0","endTime":"0","summary":"For investors wondering whether Guardant Health is still a smart buy after its massive run up, or if new investors might be late to the party, this article will walk through what the current price is really baking in.\nThe stock has surged an eye catching 214.9% over the last year and 213.9% year to date, even if the last week and month have been relatively flat at -2.3% and 0.2% respectively.\nBehind those moves, investors have been reacting to a steady drumbeat of news around Guardant's...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6032000-choice2-main-header/1585186864566","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6032000-choice2-main-header/1585186864566"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nasdaq-gh/guardant-health/news/is-it-too-late-to-consider-guardant-health-after-its-215-sur","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nasdaq-gh/guardant-health/news/is-it-too-late-to-consider-guardant-health-after-its-215-sur","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["GH","BK4585","DCF","BK4588","BK4196","BK4535","BK4551"],"gpt_icon":0},{"id":"2592180975","title":"Director Tariq Musa Reports Disposal of Guardant Health Inc. Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2592180975","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592180975?lang=en_us&edition=fundamental","pubTime":"2025-12-19 07:34","pubTimestamp":1766100848,"startTime":"0","endTime":"0","summary":"Tariq Musa, Director at Guardant Health Inc., reported a disposal of common shares of Guardant Health Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Guardant Health Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 18, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251218:nNDL1wNqBl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Director Tariq Musa Reports Disposal of Guardant Health Inc. Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4551","GH","BK4588","BK4535","BK4585","BK4196"],"gpt_icon":0},{"id":"2592993944","title":"Helmy Eltoukhy, Co-Chief Executive Officer, Reports Disposal of Guardant Health Inc. Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2592993944","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592993944?lang=en_us&edition=fundamental","pubTime":"2025-12-18 08:19","pubTimestamp":1766017158,"startTime":"0","endTime":"0","summary":"Helmy Eltoukhy, Co-Chief Executive Officer and Director of Guardant Health Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Guardant Health Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 17, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251218:nNDLb89h9H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4196","GH","BK4585","BK4588","BK4551","BK4535"],"gpt_icon":0},{"id":"2592944957","title":"Guardant Health CTO Darya Chudova Reports Sale of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2592944957","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592944957?lang=en_us&edition=fundamental","pubTime":"2025-12-18 08:18","pubTimestamp":1766017096,"startTime":"0","endTime":"0","summary":"Darya Chudova, Chief Technology Officer of Guardant Health Inc., reported a disposal of common shares of Guardant Health Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Guardant Health Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 17, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251218:nNDL7gmdww:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Guardant Health CTO Darya Chudova Reports Sale of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4551","BK4196","BK4588","BK4585","GH","BK4535"],"gpt_icon":0},{"id":"2592994451","title":"Rpt-Lantheus Holdings Inc : Mizuho Raises Target Price to $72 From $60","url":"https://stock-news.laohu8.com/highlight/detail?id=2592994451","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592994451?lang=en_us&edition=fundamental","pubTime":"2025-12-17 19:50","pubTimestamp":1765972237,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nL8N3XN0X0:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["GH","LU0106261612.USD","LU0012050646.USD","LU0205194284.USD","BK4082","BK4139","BK4196","LNTH","IE00B19Z6F94.USD","LU0205193047.USD","IE0034390439.USD","BK4167","LU2065731478.USD","LU1169590202.USD","MDXG","BK4588","IE00BLDYK493.USD","BK4535","IE00B64QTZ34.USD","BK4551","BK4198","HAE","LU1169589451.USD","INSP","BK4585"],"gpt_icon":0},{"id":"2592456994","title":"Rpt-Inspire Medical Systems Inc : Mizuho Raises Target Price to $130 From $110","url":"https://stock-news.laohu8.com/highlight/detail?id=2592456994","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592456994?lang=en_us&edition=fundamental","pubTime":"2025-12-17 19:50","pubTimestamp":1765972236,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nL8N3XN0X0:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4198","BK4082","BK4588","HAE","IE00BLDYK493.USD","IE00B19Z6F94.USD","LNTH","LU2065731478.USD","BK4167","GH","INSP","BK4585","MDXG","IE00B64QTZ34.USD","LU0205193047.USD","BK4551","LU0205194284.USD","BK4139","LU1169590202.USD","IE0034390439.USD","LU1169589451.USD","LU0012050646.USD","BK4196","LU0106261612.USD","BK4535"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.guardanthealth.com","stockEarnings":[{"period":"1week","weight":0.0829},{"period":"1month","weight":0.0736},{"period":"3month","weight":0.7155},{"period":"6month","weight":1.1924},{"period":"1year","weight":2.0109},{"period":"ytd","weight":0.0786}],"compareEarnings":[{"period":"1week","weight":0.016},{"period":"1month","weight":0.0095},{"period":"3month","weight":0.0629},{"period":"6month","weight":0.113},{"period":"1year","weight":0.1774},{"period":"ytd","weight":0.0178}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research. The company was incorporated in 2011 and is headquartered in Palo Alto, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.625,"avgChangeRate":0.066357},{"month":2,"riseRate":0.285714,"avgChangeRate":0.06426},{"month":3,"riseRate":0.571429,"avgChangeRate":-0.023739},{"month":4,"riseRate":0.428571,"avgChangeRate":-0.017651},{"month":5,"riseRate":0.571429,"avgChangeRate":0.065461},{"month":6,"riseRate":0.714286,"avgChangeRate":0.081894},{"month":7,"riseRate":0.714286,"avgChangeRate":0.051469},{"month":8,"riseRate":0.571429,"avgChangeRate":0.08346},{"month":9,"riseRate":0.285714,"avgChangeRate":-0.065825},{"month":10,"riseRate":0.285714,"avgChangeRate":0.030366},{"month":11,"riseRate":0.75,"avgChangeRate":0.130427},{"month":12,"riseRate":0.5,"avgChangeRate":-0.066498}],"exchange":"NASDAQ","name":"Guardant Health Inc.","nameEN":"Guardant Health Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Guardant Health Inc.(GH),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Guardant Health Inc.(GH) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Guardant Health Inc.,GH,Guardant Health Inc.股票,Guardant Health Inc.股票老虎,Guardant Health Inc.股票老虎国际,Guardant Health Inc.行情,Guardant Health Inc.股票行情,Guardant Health Inc.股价,Guardant Health Inc.股市,Guardant Health Inc.股票价格,Guardant Health Inc.股票交易,Guardant Health Inc.股票购买,Guardant Health Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Guardant Health Inc.(GH),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Guardant Health Inc.(GH) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction